Electro-acupuncture for SCD With Depression
NCT07350226, Not applicable, Active not recruiting, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Electro-acupuncture for SCD With Depression | ClinicalTrials.gov |
| NCT number | NCT07350226 | ClinicalTrials.gov |
| Status | Active not recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 86 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | ClinicalTrials.gov |
| Conditions | Subjective Cognitive Decline (SCD), Depression Disorder | ClinicalTrials.gov |
| Interventions | "TXJN" electro-acupuncture, Sham electroacupuncture | ClinicalTrials.gov |
| First posted | 2026-01-20 | ClinicalTrials.gov |
| Last updated | 2026-01-20 | ClinicalTrials.gov |
Registered outcomes 17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Comprehensive Cognitive Z-Score | Before and 8 weeks after treatment | This composite index of global cognitive function is derived from the aggregated Z-scores of eight neuropsychological tests (including Auditory Verbal Learning Test, Animal Fluency Test, Boston Naming Test, Trail Making Test Parts A/B, Stroop Color-Word Test-Card C, Digit Symbol Substitution Test, Digit Span Test, and Clock Drawing Test). At baseline, each test's raw scores will be standardized using the study population's mean and standard deviation (Z = \[raw score - mean\]/SD). For tests where lower scores indicate better performance (e.g., Trail Making Test time), Z-scores are reversed (multiplied by -1) to align directionality. The final aggregated Z-score, expressed in standard deviation units, will be assessed pre-treatment and 8 weeks post-treatment initiation. | ClinicalTrials.gov |
| Primary | Geriatric Depression Scale 15-Item (GDS-15) Reduction Rate | Before and 8 weeks after treatment | The reduction rate is calculated based on the total score (range: 0-15, where a higher score indicates more severe depressive symptoms) of the 15-item Geriatric Depression Scale. The reduction rate formula is: (\[Pre-treatment score - Post-treatment score\] / Pre-treatment score) × 100%. Efficacy is defined as: Markedly Effective (reduction rate ≥ 50%); Effective (50% \> reduction rate ≥ 25%); Ineffective (reduction rate \< 25%). | ClinicalTrials.gov |
| Primary | Multimodal magnetic resonance imaging indicators | Before and 8 weeks after treatment | sMRI indicators: GMV, FA, MD; rs-fMRI indicators: ALFF, fALFF, ReHo, Seed-based FC. | ClinicalTrials.gov |
| Secondary | Mini-Mental State Examination (MMSE) Total Score | Before and 8 weeks after treatment | The total score (range: 0-30) of the Mini-Mental State Examination, where a higher score indicates better cognitive function. | ClinicalTrials.gov |
| Secondary | Auditory Verbal Learning Test (AVLT) Long-Delay Free Recall Score | Before and 8 weeks after treatment | The score for the long-delay free recall trial of the Auditory Verbal Learning Test (range: 0-15 words), where a higher score indicates better episodic memory function. | ClinicalTrials.gov |
| Secondary | Rey-Osterrieth Complex Figure Test (ROCF) Delayed Recall Score | Before and 8 weeks after treatment | The score for the delayed recall trial of the Rey-Osterrieth Complex Figure Test, which is typically scored on a standardized system (e.g., 0-36 points based on accuracy and placement of reproduced elements), where a higher score indicates better visual-spatial memory and recall ability. | ClinicalTrials.gov |
| Secondary | Boston Naming Test (BNT) Total Correct Score | Before and 8 weeks after treatment | The total number of correctly named items (range: 0-30) of the 30-item Boston Naming Test, where a higher score indicates better confrontational word retrieval and language ability. | ClinicalTrials.gov |
| Secondary | Animal Fluency Test (AFT) Total Score | Before and 8 weeks after treatment | The total number of correct, unique animal names generated within 60 seconds (common score range: 0-50+), where a higher score indicates better semantic verbal fluency and executive functioning. | ClinicalTrials.gov |
| Secondary | Trail Making Test Part A (TMT-A) Completion Time | Before and 8 weeks after treatment | The time to completion (in seconds) for Trail Making Test Part A, where a shorter completion time indicates better visual attention, processing speed, and motor function. | ClinicalTrials.gov |
| Secondary | Trail Making Test Part B (TMT-B) Completion Time | Before and 8 weeks after treatment | The time to completion (in seconds) for Trail Making Test Part B, where a shorter completion time indicates better cognitive flexibility, task-switching ability, and executive function. | ClinicalTrials.gov |
| Secondary | Clock Drawing Test (CDT) Total Score | Before and 8 weeks after treatment | The total score on the standardized 30-point Clock Drawing Test (CDT30-AJ/CI version, range: 0-30), where a higher score indicates better visuospatial/executive function and cognitive integrity. | ClinicalTrials.gov |
| Secondary | Symbol Digit Modalities Test (SDMT) Correct Response Count | Before and 8 weeks after treatment | The total number of correct symbol-digit pairings completed within 90 seconds (common score range: 0-110+), where a higher score indicates better processing speed, sustained attention, and visual scanning. | ClinicalTrials.gov |
| Secondary | Pittsburgh Sleep Quality Index (PSQI) Global Score | Before and 8 weeks after treatment | The global score (range: 0-21) of the Pittsburgh Sleep Quality Index, where a higher score indicates poorer sleep quality. | ClinicalTrials.gov |
| Secondary | TCM Constitution Classification and Determination Scale - Transformed Scores | Before and 8 weeks after treatment | The transformed scores (range: 0-100 for each of the nine constitution subscales) calculated according to the standardized "TCM Constitution Classification and Determination Scale" (published by the China Association of Chinese Medicine). A higher transformed score on a specific subscale indicates a more pronounced tendency towards that constitution type (e.g., Yang Deficiency, Qi Deficiency, etc.). | ClinicalTrials.gov |
| Secondary | TCM Syndrome Type Scale for Mild Cognitive Impairment Subscale Scores | Before and 8 weeks after treatment | Scores (range: 0-30 per syndrome) for seven TCM syndrome types (e.g., Spleen-Kidney Deficiency) as assessed by the standardized "TCM Syndrome Type Scale for Mild Cognitive Impairment", where a higher score indicates more severe syndrome manifestation. | ClinicalTrials.gov |
| Other | Treatment Acceptance Survey Response | After 8 weeks of treatment | The participant's response to a single-item Treatment Acceptance Survey at the end of the treatment period. Responses are categorized as: "Completely Acceptable", "Acceptable", or "Not Acceptable". | ClinicalTrials.gov |
| Other | Incidence of Treatment-Emergent Adverse Events (TEAEs) | From treatment initiation up to 8 weeks. | The number and proportion of participants experiencing any treatment-emergent adverse event(s), classified by system organ class and severity (e.g., mild, moderate, severe), according to a standardized dictionary (e.g., MedDRA) and assessed for relationship to the study treatment. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 12
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Category Fluency | Primary outcome | ConductCognition |
| Clock Drawing Task | Primary outcome | ConductCognition |
| Digit Span Test | Primary outcome | ConductCognition |
| Picture Naming Test | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Symbol Coding | Primary outcome | ConductCognition |
| Trail Making Test A | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
| Verbal Learning | Primary outcome | ConductCognition |
| Complex Figure Copy and Recall | Secondary outcome | ConductCognition |
| Task Switching Test | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)